Not for publication or distribution, directly or indirectly, in or into the United States of America, Australia, Canada or Japan or any other jurisdiction in which such publication or distribution would be unlawful. The important notices at the end of this press release should be observed.

  • Cantourage launches new craft cultivar on the German medicinal cannabis market under New Zealand supplier Ampyl Sciences brand CannFX.
  • With this new cultivar "Lemon Berry Candy", CannFX brings another strain to the European market.
  • CannFX will supply patients in Germany, Europe and the UK, with further varieties of its premium product range launching in Q1 of 2024.

Berlin, 12 March 2024 – Cantourage Group SE (hereinafter “Cantourage”, ISIN: DE000A3DSV01,, a leading European company for the production and distribution of medical cannabis, and CannFX (, an established supplier from New Zealand, are announcing the launch of a new medicinal cannabis strain this week. The cultivar "Lemon Berry Candy", is a non-irradiated premium New Zealand cultivated strain now available to patients in Germany, further expanding their range of high-quality “Craft Cannabis” strains in the German cannabis market.

The new strain is grown for CannFX in New Zealand, who represent the majority of New Zealand growers on the international market. Its product launch represents hand-selected batches of cannabis from one of New Zealand’s top craft cultivators. CannFX plans to significantly expand its presence in the European markets this year with a number of additional strains from other New Zealand cultivators that will be launched in 2024.

Bernhard Retzer, Global Sales Director of Cantourage, commented: "We are excited to have CannFX’s next cultivar from New Zealand launched into Germany. With our unique sourcing model, we can bring cannabis flowers from growers all over the world to Germany, manufacture them into medicinal products and offer them throughout Europe. In the coming months, patients can expect further products and cultivars available in Germany and the UK."

Bastiaan Kramer, CEO of Ampyl Sciences’ brand CannFX, added: "Following our successful 2022 launch of the first New Zealand grown medicinal cannabis product into Germany and our 2023 launch of the first New Zealand grown medicinal cannabis product into the UK we are proud to now launch the Lemon Berry Candy strain into these rapidly expanding markets through our partnership with Cantourage. Our new strain has a strong terpene profile and is cultivated by one of CannFX’s most talented growers in NZ. We are pleased to be Cantourage’s exclusive New Zealand partner enabling us to bring only the highest-quality flowers from New Zealand to Germany and the UK."

About Cantourage
Cantourage is a leading European producer and distributor of cannabis flowers and cannabis-based medicinal preparations and drugs. The Berlin-based company was founded in 2019 by industry pioneers Norman Ruchholtz, Dr. Florian Holzapfel and Patrick Hoffmann. With an experienced management team and its “Fast Track Access” platform, Cantourage enables producers from around the world to become part of the growing European medical cannabis market faster, easier and more cost-effectively by processing and distributing their cannabis raw materials and extracts. In this context, Cantourage ensures compliance with the highest European pharmaceutical quality standards at all times. The company offers pharmaceutical-grade products in all relevant market segments: dried flower, extracts, dronabinol and cannabidiol. Cantourage was listed on the Frankfurt Stock Exchange on 11 November 2022 and is listed under ticker symbol “HIGH”.

More information:

About CannFX
CannFX was founded in 2019 and is the brand that represents the majority of New Zealand's medical cannabis cultivators. The company has signed agreements with only the best cultivators in New Zealand to consistently grow, produce, and distribute the cleanest and highest-grade non-irradiated medical cannabis flower. New Zealand has set the most stringent quality standards in the world for the export of non-irradiated medical cannabis. CannFX is actively working to meet and exceed these standards so that patients benefit from the highest quality dried flower available on the market.

Learn more:

This announcement does not constitute a public offer or an advertisement for a public offer for sale of securities, in particular within the meaning of Regulation (EU) 2017/1129 (Prospectus Regulation).

Press contact at Cantourage:
Tonka Communications
+49 (0)176 7471 7519